Therapeutics Acquisition Corp. (NASDAQ: RACA) Stock Competitors & Peer Comparison

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CCIV has a market cap of 44.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CCIV trades at $24.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CCIV's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CCIV's ROE of -13.92%. Regarding short-term risk, RACA is less volatile compared to CCIV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CCIV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, PSACU has a market cap of 12B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while PSACU trades at $17.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas PSACU's P/E ratio is -108.79. In terms of profitability, RACA's ROE is +0.00%, compared to PSACU's ROE of -35.44%. Regarding short-term risk, RACA is less volatile compared to PSACU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check PSACU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, RTPY has a market cap of 11.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while RTPY trades at $9.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas RTPY's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to RTPY's ROE of -0.43%. Regarding short-term risk, RACA is less volatile compared to RTPY. This indicates lower risk in terms of short-term price fluctuations for RACA.Check RTPY's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LVRAW has a market cap of 11.5B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LVRAW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LVRAW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to LVRAW's ROE of N/A. Regarding short-term risk, RACA is less volatile compared to LVRAW. This indicates lower risk in terms of short-term price fluctuations for RACA.Check LVRAW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CMLFU has a market cap of 10.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CMLFU trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CMLFU's P/E ratio is -1444.44. In terms of profitability, RACA's ROE is +0.00%, compared to CMLFU's ROE of -0.39%. Regarding short-term risk, RACA is more volatile compared to CMLFU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check CMLFU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, PSAC has a market cap of 9.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while PSAC trades at $13.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas PSAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to PSAC's ROE of -35.44%. Regarding short-term risk, RACA is less volatile compared to PSAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check PSAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GRSVU has a market cap of 6.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GRSVU trades at $11.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GRSVU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GRSVU's ROE of +0.00%. Regarding short-term risk, RACA is more volatile compared to GRSVU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check GRSVU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, APSG has a market cap of 6.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while APSG trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas APSG's P/E ratio is 36.95. In terms of profitability, RACA's ROE is +0.00%, compared to APSG's ROE of +0.03%. Regarding short-term risk, RACA is less volatile compared to APSG. This indicates lower risk in terms of short-term price fluctuations for RACA.Check APSG's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, RTP has a market cap of 6.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while RTP trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas RTP's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to RTP's ROE of -0.58%. Regarding short-term risk, RACA is more volatile compared to RTP. This indicates higher risk in terms of short-term price fluctuations for RACA.Check RTP's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DGNR has a market cap of 5.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DGNR trades at $9.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DGNR's P/E ratio is -308.67. In terms of profitability, RACA's ROE is +0.00%, compared to DGNR's ROE of +0.02%. Regarding short-term risk, RACA is more volatile compared to DGNR. This indicates higher risk in terms of short-term price fluctuations for RACA.Check DGNR's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, VTIQ has a market cap of 5.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while VTIQ trades at $10.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas VTIQ's P/E ratio is 91.50. In terms of profitability, RACA's ROE is +0.00%, compared to VTIQ's ROE of +472.81%. Regarding short-term risk, RACA is more volatile compared to VTIQ. This indicates higher risk in terms of short-term price fluctuations for RACA.Check VTIQ's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, VTIQU has a market cap of 5.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while VTIQU trades at $10.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas VTIQU's P/E ratio is 100.60. In terms of profitability, RACA's ROE is +0.00%, compared to VTIQU's ROE of +472.81%. Regarding short-term risk, RACA is more volatile compared to VTIQU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check VTIQU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, VACQ has a market cap of 5.5B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while VACQ trades at $11.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas VACQ's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to VACQ's ROE of -0.12%. Regarding short-term risk, RACA is less volatile compared to VACQ. This indicates lower risk in terms of short-term price fluctuations for RACA.Check VACQ's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SVFC has a market cap of 5.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SVFC trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SVFC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SVFC's ROE of +0.05%. Regarding short-term risk, RACA is less volatile compared to SVFC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SVFC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, VGAC has a market cap of 5B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while VGAC trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas VGAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to VGAC's ROE of -1.21%. Regarding short-term risk, RACA is less volatile compared to VGAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check VGAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CMLT has a market cap of 4.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CMLT trades at $8.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CMLT's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CMLT's ROE of N/A. Regarding short-term risk, RACA is less volatile compared to CMLT. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CMLT's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GHVI has a market cap of 4.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GHVI trades at $14.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GHVI's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GHVI's ROE of -1.28%. Regarding short-term risk, RACA is less volatile compared to GHVI. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GHVI's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, KVSB has a market cap of 4.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while KVSB trades at $11.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas KVSB's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to KVSB's ROE of -0.07%. Regarding short-term risk, RACA is less volatile compared to KVSB. This indicates lower risk in terms of short-term price fluctuations for RACA.Check KVSB's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FTOCU has a market cap of 4.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FTOCU trades at $11.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FTOCU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FTOCU's ROE of +0.07%. Regarding short-term risk, RACA is more volatile compared to FTOCU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check FTOCU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, THCBU has a market cap of 3.9B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while THCBU trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas THCBU's P/E ratio is -101.87. In terms of profitability, RACA's ROE is +0.00%, compared to THCBU's ROE of -0.23%. Regarding short-term risk, RACA is less volatile compared to THCBU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check THCBU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CLII has a market cap of 3.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CLII trades at $14.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CLII's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CLII's ROE of -0.31%. Regarding short-term risk, RACA is less volatile compared to CLII. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CLII's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GRNV has a market cap of 3.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GRNV trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GRNV's P/E ratio is -59.68. In terms of profitability, RACA's ROE is +0.00%, compared to GRNV's ROE of +0.05%. Regarding short-term risk, RACA is less volatile compared to GRNV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GRNV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FRX has a market cap of 3.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FRX trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FRX's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FRX's ROE of +0.19%. Regarding short-term risk, RACA is less volatile compared to FRX. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FRX's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HOLUU has a market cap of 3.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HOLUU trades at $13.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HOLUU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HOLUU's ROE of -0.13%. Regarding short-term risk, RACA is less volatile compared to HOLUU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check HOLUU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SSPK has a market cap of 3.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SSPK trades at $18.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SSPK's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SSPK's ROE of +0.04%. Regarding short-term risk, RACA is less volatile compared to SSPK. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SSPK's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FCACU has a market cap of 3.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FCACU trades at $9.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FCACU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FCACU's ROE of -0.00%. Regarding short-term risk, RACA is less volatile compared to FCACU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FCACU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CFVI has a market cap of 3.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CFVI trades at $12.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CFVI's P/E ratio is -18.55. In terms of profitability, RACA's ROE is +0.00%, compared to CFVI's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to CFVI. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CFVI's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HOL has a market cap of 3.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HOL trades at $12.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HOL's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HOL's ROE of -0.13%. Regarding short-term risk, RACA is less volatile compared to HOL. This indicates lower risk in terms of short-term price fluctuations for RACA.Check HOL's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CCXIW has a market cap of 3.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CCXIW trades at $8.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CCXIW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CCXIW's ROE of N/A. Regarding short-term risk, RACA is less volatile compared to CCXIW. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CCXIW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, THCB has a market cap of 3.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while THCB trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas THCB's P/E ratio is -81.30. In terms of profitability, RACA's ROE is +0.00%, compared to THCB's ROE of -0.23%. Regarding short-term risk, RACA is less volatile compared to THCB. This indicates lower risk in terms of short-term price fluctuations for RACA.Check THCB's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SOAC has a market cap of 2.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SOAC trades at $10.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SOAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SOAC's ROE of +3.51%. Regarding short-term risk, RACA is less volatile compared to SOAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SOAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DCRBU has a market cap of 2.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DCRBU trades at $11.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DCRBU's P/E ratio is -16.00. In terms of profitability, RACA's ROE is +0.00%, compared to DCRBU's ROE of -0.84%. Regarding short-term risk, RACA is less volatile compared to DCRBU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DCRBU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, IVAN has a market cap of 2.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while IVAN trades at $7.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas IVAN's P/E ratio is -698.18. In terms of profitability, RACA's ROE is +0.00%, compared to IVAN's ROE of -0.32%. Regarding short-term risk, RACA is less volatile compared to IVAN. This indicates lower risk in terms of short-term price fluctuations for RACA.Check IVAN's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GWAC has a market cap of 2.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GWAC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GWAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GWAC's ROE of -0.59%. Regarding short-term risk, RACA is less volatile compared to GWAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GWAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LCYAU has a market cap of 2.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LCYAU trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LCYAU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to LCYAU's ROE of +0.04%. Regarding short-term risk, RACA is more volatile compared to LCYAU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check LCYAU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FWAA has a market cap of 2.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FWAA trades at $12.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FWAA's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FWAA's ROE of -0.09%. Regarding short-term risk, RACA is less volatile compared to FWAA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FWAA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GSAH has a market cap of 2.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GSAH trades at $10.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GSAH's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GSAH's ROE of +0.42%. Regarding short-term risk, RACA is more volatile compared to GSAH. This indicates higher risk in terms of short-term price fluctuations for RACA.Check GSAH's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LCY has a market cap of 2.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LCY trades at $12.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LCY's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to LCY's ROE of +0.04%. Regarding short-term risk, RACA is more volatile compared to LCY. This indicates higher risk in terms of short-term price fluctuations for RACA.Check LCY's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FORE has a market cap of 2.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FORE trades at $9.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FORE's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FORE's ROE of +4.34%. Regarding short-term risk, RACA is less volatile compared to FORE. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FORE's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, RAAC has a market cap of 2.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while RAAC trades at $9.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas RAAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to RAAC's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to RAAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check RAAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SPNV has a market cap of 2.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SPNV trades at $8.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SPNV's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SPNV's ROE of -0.99%. Regarding short-term risk, RACA is less volatile compared to SPNV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SPNV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DNAC has a market cap of 2.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DNAC trades at $9.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DNAC's P/E ratio is -37.72. In terms of profitability, RACA's ROE is +0.00%, compared to DNAC's ROE of -0.34%. Regarding short-term risk, RACA is less volatile compared to DNAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DNAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FAII has a market cap of 2.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FAII trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FAII's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FAII's ROE of -0.32%. Regarding short-term risk, RACA is less volatile compared to FAII. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FAII's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DMYI has a market cap of 2.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DMYI trades at $10.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DMYI's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to DMYI's ROE of -0.16%. Regarding short-term risk, RACA is less volatile compared to DMYI. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DMYI's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LOKB has a market cap of 2.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LOKB trades at $13.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LOKB's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to LOKB's ROE of -0.62%. Regarding short-term risk, RACA is less volatile compared to LOKB. This indicates lower risk in terms of short-term price fluctuations for RACA.Check LOKB's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, STPC has a market cap of 2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while STPC trades at $9.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas STPC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to STPC's ROE of -0.29%. Regarding short-term risk, RACA is more volatile compared to STPC. This indicates higher risk in terms of short-term price fluctuations for RACA.Check STPC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, MUDS has a market cap of 2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while MUDS trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas MUDS's P/E ratio is 3.39. In terms of profitability, RACA's ROE is +0.00%, compared to MUDS's ROE of -0.01%. Regarding short-term risk, RACA is more volatile compared to MUDS. This indicates higher risk in terms of short-term price fluctuations for RACA.Check MUDS's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, MUDSU has a market cap of 2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while MUDSU trades at $10.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas MUDSU's P/E ratio is -1125.56. In terms of profitability, RACA's ROE is +0.00%, compared to MUDSU's ROE of -0.01%. Regarding short-term risk, RACA is more volatile compared to MUDSU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check MUDSU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, TINV has a market cap of 2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while TINV trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas TINV's P/E ratio is 30.61. In terms of profitability, RACA's ROE is +0.00%, compared to TINV's ROE of +1.23%. Regarding short-term risk, RACA is less volatile compared to TINV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check TINV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, APXT has a market cap of 1.9B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while APXT trades at $10.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas APXT's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to APXT's ROE of +0.16%. Regarding short-term risk, RACA is more volatile compared to APXT. This indicates higher risk in terms of short-term price fluctuations for RACA.Check APXT's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, APXTU has a market cap of 1.9B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while APXTU trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas APXTU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to APXTU's ROE of +0.16%. Regarding short-term risk, RACA is more volatile compared to APXTU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check APXTU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DWAC has a market cap of 1.9B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DWAC trades at $49.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DWAC's P/E ratio is -73.46. In terms of profitability, RACA's ROE is +0.00%, compared to DWAC's ROE of -0.58%. Regarding short-term risk, RACA is less volatile compared to DWAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DWAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DWACU has a market cap of 1.9B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DWACU trades at $61.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DWACU's P/E ratio is -451.10. In terms of profitability, RACA's ROE is +0.00%, compared to DWACU's ROE of -0.58%. Regarding short-term risk, RACA is less volatile compared to DWACU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DWACU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ATHN has a market cap of 1.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ATHN trades at $9.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ATHN's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to ATHN's ROE of +2.24%. Regarding short-term risk, RACA is less volatile compared to ATHN. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ATHN's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, APXTW has a market cap of 1.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while APXTW trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas APXTW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to APXTW's ROE of +0.16%. Regarding short-term risk, RACA is less volatile compared to APXTW. This indicates lower risk in terms of short-term price fluctuations for RACA.Check APXTW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GMII has a market cap of 1.8B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GMII trades at $8.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GMII's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GMII's ROE of +0.21%. Regarding short-term risk, RACA is less volatile compared to GMII. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GMII's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, MOTV has a market cap of 1.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while MOTV trades at $10.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas MOTV's P/E ratio is 55.86. In terms of profitability, RACA's ROE is +0.00%, compared to MOTV's ROE of -0.23%. Regarding short-term risk, RACA is less volatile compared to MOTV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check MOTV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CBAH has a market cap of 1.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CBAH trades at $10.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CBAH's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CBAH's ROE of +0.04%. Regarding short-term risk, RACA is less volatile compared to CBAH. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CBAH's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GXGXU has a market cap of 1.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GXGXU trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GXGXU's P/E ratio is -23.73. In terms of profitability, RACA's ROE is +0.00%, compared to GXGXU's ROE of -0.03%. Regarding short-term risk, RACA is less volatile compared to GXGXU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GXGXU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, AONE has a market cap of 1.7B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while AONE trades at $8.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas AONE's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to AONE's ROE of -17.11%. Regarding short-term risk, RACA is less volatile compared to AONE. This indicates lower risk in terms of short-term price fluctuations for RACA.Check AONE's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SNPR has a market cap of 1.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SNPR trades at $9.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SNPR's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SNPR's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to SNPR. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SNPR's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SPFR has a market cap of 1.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SPFR trades at $8.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SPFR's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SPFR's ROE of -4.58%. Regarding short-term risk, RACA is less volatile compared to SPFR. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SPFR's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DEH has a market cap of 1.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DEH trades at $11.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DEH's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to DEH's ROE of -3.33%. Regarding short-term risk, RACA is less volatile compared to DEH. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DEH's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ROT has a market cap of 1.6B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ROT trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ROT's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to ROT's ROE of -0.45%. Regarding short-term risk, RACA is less volatile compared to ROT. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ROT's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, NGAC has a market cap of 1.5B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while NGAC trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas NGAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to NGAC's ROE of -0.87%. Regarding short-term risk, RACA is less volatile compared to NGAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check NGAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, GXGX has a market cap of 1.5B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while GXGX trades at $10.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas GXGX's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to GXGX's ROE of +4.12%. Regarding short-term risk, RACA is less volatile compared to GXGX. This indicates lower risk in terms of short-term price fluctuations for RACA.Check GXGX's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HECCU has a market cap of 1.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HECCU trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HECCU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HECCU's ROE of -0.10%. Regarding short-term risk, RACA is less volatile compared to HECCU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check HECCU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ATMR has a market cap of 1.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ATMR trades at $10.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ATMR's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to ATMR's ROE of +0.44%. Regarding short-term risk, RACA is less volatile compared to ATMR. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ATMR's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SFTW has a market cap of 1.4B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SFTW trades at $11.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SFTW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SFTW's ROE of -0.56%. Regarding short-term risk, RACA is less volatile compared to SFTW. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SFTW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ENFA has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ENFA trades at $9.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ENFA's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to ENFA's ROE of -1.15%. Regarding short-term risk, RACA is less volatile compared to ENFA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ENFA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ENVI has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ENVI trades at $8.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ENVI's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to ENVI's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to ENVI. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ENVI's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, ACTD has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while ACTD trades at $7.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas ACTD's P/E ratio is -25.50. In terms of profitability, RACA's ROE is +0.00%, compared to ACTD's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to ACTD. This indicates lower risk in terms of short-term price fluctuations for RACA.Check ACTD's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, VCKA has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while VCKA trades at $9.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas VCKA's P/E ratio is 100.11. In terms of profitability, RACA's ROE is +0.00%, compared to VCKA's ROE of +1.68%. Regarding short-term risk, RACA is less volatile compared to VCKA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check VCKA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, THMA has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while THMA trades at $9.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas THMA's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to THMA's ROE of +0.00%. Regarding short-term risk, RACA is more volatile compared to THMA. This indicates higher risk in terms of short-term price fluctuations for RACA.Check THMA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LNFA has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LNFA trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LNFA's P/E ratio is 21.06. In terms of profitability, RACA's ROE is +0.00%, compared to LNFA's ROE of +0.09%. Regarding short-term risk, RACA is less volatile compared to LNFA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check LNFA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FTIVU has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FTIVU trades at $14.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FTIVU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FTIVU's ROE of -0.14%. Regarding short-term risk, RACA is less volatile compared to FTIVU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FTIVU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, STWO has a market cap of 1.3B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while STWO trades at $8.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas STWO's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to STWO's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to STWO. This indicates lower risk in terms of short-term price fluctuations for RACA.Check STWO's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HYACU has a market cap of 1.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HYACU trades at $10.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HYACU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HYACU's ROE of -0.11%. Regarding short-term risk, RACA is more volatile compared to HYACU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check HYACU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FTIV has a market cap of 1.2B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FTIV trades at $13.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FTIV's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FTIV's ROE of -0.14%. Regarding short-term risk, RACA is less volatile compared to FTIV. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FTIV's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, AHAC has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while AHAC trades at $10.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas AHAC's P/E ratio is -72.11. In terms of profitability, RACA's ROE is +0.00%, compared to AHAC's ROE of -16.18%. Regarding short-term risk, RACA is less volatile compared to AHAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check AHAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, AMHC has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while AMHC trades at $10.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas AMHC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to AMHC's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to AMHC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check AMHC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HERA has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HERA trades at $10.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HERA's P/E ratio is 46.32. In terms of profitability, RACA's ROE is +0.00%, compared to HERA's ROE of +0.01%. Regarding short-term risk, RACA is more volatile compared to HERA. This indicates higher risk in terms of short-term price fluctuations for RACA.Check HERA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HERAW has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HERAW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HERAW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HERAW's ROE of +0.01%. Regarding short-term risk, RACA is less volatile compared to HERAW. This indicates lower risk in terms of short-term price fluctuations for RACA.Check HERAW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FGNA has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FGNA trades at $9.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FGNA's P/E ratio is -4.35. In terms of profitability, RACA's ROE is +0.00%, compared to FGNA's ROE of +0.71%. Regarding short-term risk, RACA is less volatile compared to FGNA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check FGNA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, DNAA has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while DNAA trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas DNAA's P/E ratio is -54.53. In terms of profitability, RACA's ROE is +0.00%, compared to DNAA's ROE of +0.00%. Regarding short-term risk, RACA is less volatile compared to DNAA. This indicates lower risk in terms of short-term price fluctuations for RACA.Check DNAA's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, TREB has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while TREB trades at $9.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas TREB's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to TREB's ROE of -12.26%. Regarding short-term risk, RACA is less volatile compared to TREB. This indicates lower risk in terms of short-term price fluctuations for RACA.Check TREB's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, PACE has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while PACE trades at $11.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas PACE's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to PACE's ROE of -1.52%. Regarding short-term risk, RACA is less volatile compared to PACE. This indicates lower risk in terms of short-term price fluctuations for RACA.Check PACE's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, HERAU has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while HERAU trades at $10.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas HERAU's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to HERAU's ROE of +0.01%. Regarding short-term risk, RACA is more volatile compared to HERAU. This indicates higher risk in terms of short-term price fluctuations for RACA.Check HERAU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, LSAQ has a market cap of 1.1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while LSAQ trades at $9.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas LSAQ's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to LSAQ's ROE of N/A. Regarding short-term risk, RACA is less volatile compared to LSAQ. This indicates lower risk in terms of short-term price fluctuations for RACA.Check LSAQ's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SRAC has a market cap of 1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SRAC trades at $10.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SRAC's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SRAC's ROE of -4.03%. Regarding short-term risk, RACA is less volatile compared to SRAC. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SRAC's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, FTPAW has a market cap of 1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while FTPAW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas FTPAW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to FTPAW's ROE of -0.00%. Regarding short-term risk, RACA is more volatile compared to FTPAW. This indicates higher risk in terms of short-term price fluctuations for RACA.Check FTPAW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, SBG has a market cap of 1B. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while SBG trades at $8.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas SBG's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to SBG's ROE of -3.15%. Regarding short-term risk, RACA is less volatile compared to SBG. This indicates lower risk in terms of short-term price fluctuations for RACA.Check SBG's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CVII-WT has a market cap of 977.9M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CVII-WT trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CVII-WT's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to CVII-WT's ROE of +0.02%. Regarding short-term risk, RACA is more volatile compared to CVII-WT. This indicates higher risk in terms of short-term price fluctuations for RACA.Check CVII-WT's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, BBCQW has a market cap of 977.6M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while BBCQW trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas BBCQW's P/E ratio is N/A. In terms of profitability, RACA's ROE is +0.00%, compared to BBCQW's ROE of N/A. Regarding short-term risk, RACA is more volatile compared to BBCQW. This indicates higher risk in terms of short-term price fluctuations for RACA.Check BBCQW's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CVII-UN has a market cap of 958.8M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CVII-UN trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CVII-UN's P/E ratio is 64.65. In terms of profitability, RACA's ROE is +0.00%, compared to CVII-UN's ROE of +0.02%. Regarding short-term risk, RACA is less volatile compared to CVII-UN. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CVII-UN's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, BRPM has a market cap of 944M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while BRPM trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas BRPM's P/E ratio is -72.74. In terms of profitability, RACA's ROE is +0.00%, compared to BRPM's ROE of +4.56%. Regarding short-term risk, RACA is less volatile compared to BRPM. This indicates lower risk in terms of short-term price fluctuations for RACA.Check BRPM's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CRSAU has a market cap of 937.8M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CRSAU trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CRSAU's P/E ratio is -27.21. In terms of profitability, RACA's ROE is +0.00%, compared to CRSAU's ROE of -0.34%. Regarding short-term risk, RACA is less volatile compared to CRSAU. This indicates lower risk in terms of short-term price fluctuations for RACA.Check CRSAU's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, CVII has a market cap of 914.7M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while CVII trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas CVII's P/E ratio is 999.00. In terms of profitability, RACA's ROE is +0.00%, compared to CVII's ROE of +0.02%. Regarding short-term risk, RACA is more volatile compared to CVII. This indicates higher risk in terms of short-term price fluctuations for RACA.Check CVII's competition here

Therapeutics Acquisition Corp. (NASDAQ: RACA) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RACA stands at 1.1B. In comparison, BCTG has a market cap of 899.4M. Regarding current trading prices, RACA is priced at $10.27 on the NASDAQ, while BCTG trades at $10.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RACA currently has a P/E ratio of N/A, whereas BCTG's P/E ratio is -204.00. In terms of profitability, RACA's ROE is +0.00%, compared to BCTG's ROE of -0.42%. Regarding short-term risk, RACA is less volatile compared to BCTG. This indicates lower risk in terms of short-term price fluctuations for RACA.Check BCTG's competition here